Drug Profile
Bromhexine hydrochloride - WanBangDe Pharmaceutical Group
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator WanBangDe Pharmaceutical Group Co., Ltd.
- Class Aniline compounds; Antibronchitics; Antivirals; Benzene derivatives; Cyclohexylamines; Expectorants; Mucolytics; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID-19 pneumonia
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in China (PO, Tablet)
- 17 Dec 2020 Wanbangde Pharmaceutical plans a phase I trial for COVID-19 pneumonia (In volunteers) (PO, Tablet) in December 2021 (NCT04672707)
- 16 Feb 2020 Clinical trials in COVID-19 pneumonia in China (PO) (NCT04273763)